Education
About Us
Working with TipRanks
Follow Us
Immuno-Biological Laboratories Co., Ltd. (JP:4570)
:4570
Top Page
Immuno-Biological Laboratories Co., Ltd.
(4570)
Select Model
Select Model
Rating:69Neutral
Price Target:
¥519.00
▲(8.35% Upside)
Immuno-Biological Laboratories shows strong financial performance with improved profitability and efficient operations, contributing significantly to the score. The technical analysis indicates a neutral to slightly bearish trend, while the valuation suggests the stock is reasonably priced. The absence of earnings call data and corporate events means these factors do not influence the score.
Immuno-Biological Laboratories Co., Ltd. (4570) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥4.42B
Dividend YieldN/A
Average Volume (3M)25.63K
Price to Earnings (P/E)17.3
Beta (1Y)0.95
Revenue Growth9.47%
EPS Growth14.00%
CountryJP
Employees57
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)6.54
Shares Outstanding9,314,590
10 Day Avg. Volume36,120
30 Day Avg. Volume25,630
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)2.95
Price to Sales (P/S)4.61
P/FCF Ratio36.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥549.00Price Target Upside14.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Immuno-Biological Laboratories Co., Ltd. Business Overview & Revenue Model
Company DescriptionImmuno-Biological Laboratories Co., Ltd. (4570) is a biotechnology company specializing in the research, development, manufacturing, and distribution of diagnostic reagents and therapeutic products. The company operates in the life sciences sector, providing innovative solutions to support healthcare professionals and researchers in diagnosing and treating various medical conditions. Its core products include immunological and biochemical reagents for laboratory use, as well as pharmaceuticals aimed at improving patient care.
How the Company Makes MoneyImmuno-Biological Laboratories Co., Ltd. generates revenue primarily through the sale of its diagnostic reagents and therapeutic products to healthcare providers, research institutions, and laboratories. The company’s revenue streams include product sales, contract research and development services, and potential licensing agreements. Additionally, partnerships with academic institutions and other biotech companies can contribute to its earnings by expanding its product offerings and market reach. The company's focus on innovation and quality drives customer demand and maintains its competitive edge in the biotechnology sector.
Immuno-Biological Laboratories Co., Ltd. Financial Statement Overview
Summary
Immuno-Biological Laboratories exhibits a commendable financial trajectory with consistent revenue growth, improved profitability, and sound balance sheet management. The company has strong margins and cash flow generation, indicating efficient operations and a successful turnaround from past losses.Income Statement
Immuno-Biological Laboratories has demonstrated strong revenue growth over the years. The gross profit margin is robust at 64.8% for 2025, indicating efficient cost management. The net profit margin improved significantly to 25.7% in 2025, showing a turnaround from losses in previous years. Both EBIT and EBITDA margins have improved, reflecting better operational efficiency.78
Positive
Balance Sheet
The company maintains a strong balance sheet with a low debt-to-equity ratio of 0.13 in 2025, indicating prudent leverage. A high equity ratio of 82.0% suggests strong capitalization. The return on equity stands at 16.4%, reflecting improved profitability and efficient use of equity.75
Positive
Cash Flow
The operating cash flow has increased significantly, supporting positive free cash flow growth. The operating cash flow to net income ratio is 0.74, indicating strong cash generation relative to profitability. The company has shown consistent improvement in cash flow management, enhancing financial flexibility.72
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 951.89M | 969.53M | 816.70M | 794.62M | 647.58M | 602.75M |
| Gross Profit | 632.07M | 628.34M | 517.29M | 526.71M | 376.70M | 346.86M |
| EBITDA | 225.22M | 226.55M | 128.11M | -332.00M | -249.50M | -309.88M |
| Net Income | 258.63M | 249.05M | 186.69M | -289.73M | -258.77M | -318.83M |
Balance Sheet | ||||||
| Total Assets | 1.92B | 1.85B | 1.62B | 1.43B | 1.71B | 1.84B |
| Cash, Cash Equivalents and Short-Term Investments | 903.75M | 825.73M | 734.14M | 614.16M | 508.35M | 604.19M |
| Total Debt | 196.94M | 204.23M | 235.98M | 234.99M | 234.00M | 90.00M |
| Total Liabilities | 343.43M | 331.03M | 353.27M | 355.72M | 336.99M | 208.76M |
| Stockholders Equity | 1.58B | 1.51B | 1.27B | 1.08B | 1.37B | 1.63B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 123.83M | 115.11M | 26.46M | -93.20M | -207.60M |
| Operating Cash Flow | 0.00 | 183.50M | 133.78M | 26.46M | -93.20M | -194.15M |
| Investing Cash Flow | 0.00 | -53.66M | -24.50M | 30.04M | -155.63M | -17.23M |
| Financing Cash Flow | 0.00 | -31.75M | 991.00K | 991.00K | 144.00M | -216.00M |
Immuno-Biological Laboratories Co., Ltd. Technical Analysis
Neutral
479.00
Price Trends
483.06
Negative
494.36
Negative
484.35
Negative
Market Momentum
-1.98
Negative
53.97
Neutral
36.18
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4570, the sentiment is Neutral. The current price of 479 is above the 20-day moving average (MA) of 473.30, below the 50-day MA of 483.06, and below the 200-day MA of 484.35, indicating a neutral trend. The MACD of -1.98 indicates Negative momentum. The RSI at 53.97 is Neutral, neither overbought nor oversold. The STOCH value of 36.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4570.
Immuno-Biological Laboratories Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | ¥4.42B | 17.28 | ― | ― | 9.47% | 14.00% | |
54 Neutral | ¥3.26B | ― | ― | ― | -8.56% | -7.26% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | ¥7.57B | ― | ― | ― | 1254.76% | 33.94% | |
38 Underperform | ¥4.46B | ― | ― | ― | 965.85% | -42.78% | |
37 Underperform | ¥4.93B | ― | ― | ― | -59.53% | 11.70% | |
28 Underperform | ¥6.15B | ― | ― | ― | ― | 20.41% |
* Healthcare Sector Average
JP:4570
Immuno-Biological Laboratories Co., Ltd.
479.00
54.00
12.71%
JP:4591
Ribomic, Inc.
96.00
18.00
23.08%
JP:4594
BrightPath Biotherapeutics Co.Ltd.
65.00
18.00
38.30%
JP:4598
Delta-Fly Pharma, Inc.
552.00
29.00
5.54%
JP:4881
FunPep Company Limited
109.00
-21.00
-16.15%
JP:4884
Kringle Pharma, Inc.
457.00
-396.00
-46.42%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.